Reactions 1304 - 5 Jun 2010

1

■ Roche and Biogen Idec have announced that they will discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis (RA). The companies concluded that the overall benefit to risk profile of ocrelizumab was not favourable in RA, based on a detailed analysis of the efficacy and safety results from the programme, and taking into account currently available treatment options. Roche, et al. Roche and Biogen Idec announce their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis. Media Release : 19 May 2010. Available from: URL: http:// 809112734 www.roche.com

0114-9954/10/1304-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Reactions 5 Jun 2010 No. 1304